Αρχική World News GreaterGood’s Inaugural Breast Cancer Research Professor Is Changing the Face of Cancer...

GreaterGood’s Inaugural Breast Cancer Research Professor Is Changing the Face of Cancer Research

GreaterGood is excited to introduce Dr. Sofía Merajver, MD, PhD, of the University of Michigan, as our inaugural breast cancer research professor. We can’t wait for you to meet this amazing woman, who has been dedicated to medical research since she was just five years old and is now changing the face of breast cancer research!

Dr. Merajver grew up in Buenos Aires, Argentina. Her family had no TV and no car, but still, she says, she was surrounded by books and led an exciting life of curiosity.

When she was five years old, Dr. Merajver’s family took her to say goodbye to her uncle, who was dying of an unknown respiratory disease. She was determined to figure out what was wrong with him, so she began asking him questions. He had a high fever and told her that it hurt to breathe, and she asked whether it hurt while he breathed in or out. He said it hurt at the very end of the breath in just one spot, and Dr. Merajver decided that it must be an infection of the diaphragm, which she promptly told the doctors. She didn’t know the word for “abscess” at the time, but she described it as a ball in the diaphragm, and the doctors immediately knew what she was talking about.

Photo Credit: Leisa Thompson Photography

“They opened him up and took it out, and he lived for another 40 years,” she recalls. “That week, I decided I was going to be a scientist.”

Later, when she was 15, Dr. Merajver also treated her father, who smoked and was dying of lung cancer. At the time, there were no real opportunities for treatment, but there was a clinical trial being conducted, and researchers in Buenos Aires were participating. After reading about the trial, Dr. Merajver went to the institute and asked if her father could come to be treated there. They couldn’t let him into the trial, but they happened to have some leftover drugs that weren’t expired, and they agreed to give them to Dr. Merajver.

“I borrowed a glass syringe that my mother boiled in the kitchen, and I gave my dad chemotherapy,” says Dr. Merajver. “And he responded pretty well, I would think. He lived another six months. He had the worst location for lung cancer; I knew he didn’t have long at all. Just weeks, really.”

Photo Credit: Leisa Thompson Photography

Dr. Merajver left Argentina and came to the United States to get her Ph.D. in physics and went to medical school at the University of Michigan. She is now a professor of international medicine and epidemiology, a Rogel Scholar, and the director of the Breast and Ovarian Cancer Risk Evaluation Program at the University of Michigan.

Among other projects, Dr. Merajver and her team use multidisciplinary strategies to combat breast cancer metastases in the brain, which is the most lethal complication of cancer disease progression. They work both in the lab and directly with patients, using their findings in each setting to inform their decisions in the other.

The team takes tumors directly from surgery to the lab, where they slice them up, isolate the cancer cells, and analyze them against a database of cancer medications to determine which drugs are most likely to be effective.

Photo Credit: Leisa Thompson Photography

“Now this person doesn’t have years of her life to be receiving drugs that don’t work,” Dr. Merajver says about a particular tissue sample from a metastatic breast cancer patient. “They should receive only the drugs that have a good chance of working. The reality is that most of the drugs are going to be ineffective, but we can tell which ones will be effective.”

The process usually takes just a few days, and then they’re able to get a treatment plan into place quickly for their patients. With metastatic cancer, time is of the essence, so it’s imperative that the information be relayed as quickly as possible.

Photo Credit: Leisa Thompson Photography

Dr. Merajver’s team is one of the few working on brain metastasis projects, and they have the largest collection in the world of brain metastasis samples. They’re also the only team on the planet that can currently get this information synthesized in such a short period of time so that patients can get the right treatment as quickly as possible.

Someone is available 24 hours a day, seven days a week, so that whenever a cancerous tissue is extracted from a patient, it can be collected and analyzed. “We never miss a tissue,” says Dr. Merajver.

Dr. Merajver believes her team has a very good chance of stabilizing the survival curves that currently exist for metastatic patients and pushing out the expected survival time by several years. This is extra important for young patients whose lifespans would be cut short by cancer by several decades without proper treatment.

Photo Credit: Leisa Thompson Photography

However, even with such a vital research project, it has proven difficult to get funding. For five years, the project has only moved forward with the help of philanthropy. Now with GreaterGood and donors like you backing her funding, Dr. Merajver will be able to help so many more people.

“Every dollar is used for research—basically nothing else,” says Dr. Merajver.

GreaterGood would like to thank Dr. Merajver, as well as each of the members of her team: Jason Heth, MD; Aki Morikawa, MD, PhD; Matt Soellner, PhD; Maria G.Castro, PhD; Carlos A. Aguilar, PhD; Trisha Westerhof, PhD; C. Ryan Oliver, PhD; and Nathan Merrill, PhD.

Photo Credit: Leisa Thompson Photography

“What you are doing is really helping save lives while nurturing the career of [these] wonderful people,” says Dr. Merajver. “I would get very little done if I were doing it myself.”

In funding this breast cancer research professorship, GreaterGood aims to create opportunities for innovation in the field of cancer research and to make a significant impact on those affected by cancer for years to come. We’re honored to be able to fund this vital work!

Elizabeth Nelson

Elizabeth Nelson is a wordsmith, an alumna of Aquinas College in Grand Rapids, a four-leaf-clover finder, and a grammar connoisseur. She has lived in west Michigan since age four but loves to travel to new (and old) places. In her free time, she. . . wait, what’s free time?

Provide Mammograms

Support those fighting Breast Cancer at The Breast Cancer Site for free!

Whizzco Source


Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...


Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...


ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

Avapritinib Not Superior to Regorafenib in Terms of Median PFS in Third-Line or Later Treatment of Patients with Unresectable or Metastatic GIST

Findings from an open-label, randomised, multicentre phase III VOYAGER study indicate that avapritinib is not superior to regorafenib in terms of median progression-free survival...

Patients less likely to rate cancer care as ‘very good’ during pandemic

Almost a third of cancer patients have reported receiving worse care since COVID-19 began, according to a new survey commissioned by Cancer Research UK. Whilst...

How to Avoid Spreading Harmful Chemo Chemicals to Members of Your Household

Cancer is not contagious, and neither is chemotherapy. However, harmful chemotherapy drugs can sometimes still be present in the bodily fluids of a person...

Can’t Sleep? Tips for Coping with Insomnia

Insomnia* is common for cancer patients**, as well as for the general population. We frequently hear from our patients and their caregivers that sleeping through the night...

New Task Force Focuses on Quality of Life for AYAs with Cancer

August 4, 2021, by NCI Staff Adolescents and young adults are using mobile devices to document the impact of cancer and its treatment on their...

Amivantamab Demonstrates Robust Efficacy in Patients with EGFR Exon 20 Insertion-Mutated NSCLC

Amivantamab demonstrated robust and durable responses in patients with epidermal growth factor receptor Exon 20 insertion (EGFR Exon20ins)-mutated non-small cell lung cancer (NSCLC) after progression on...